Clinical Guidelines

Light-activated Suprachoroidal Therapy for the First-line Treatment of Indeterminate Lesions and Small Choroidal Melanoma

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Share

This article discusses a novel virus-like drug conjugate (VDC), AU-011, developed for the treatment of indeterminate lesions and small choroidal melanomas, as well as potentially other ocular oncology indications. AU-011 has a dual mechanism of action, consisting of acute necrosis and immune activation, and its tumor targeting is driven by the binding of the VDC to modified heparan sulfate proteoglycans on the tumor cell membrane. The preliminary safety data from the ongoing phase 2 trial using suprachoroidal administration supports the continued dose escalation. The article additionally highlights the potential for treating choroidal metastasis with AU-011. The authors are Hakan Demirci, MD, and Buse Guneri Beser, MD, and the article is part of a series supported by Bausch + Lomb.

Original Source(s)

Light-activated Suprachoroidal Therapy for the First-line Treatment of Indeterminate Lesions and Small Choroidal Melanoma

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

  • by Buse Guneri Beser, MD, FEBO, FICO, Hakan Demirci, MD

  • August 1, 2022

  • 10 min

Related Content

Patterns of Spread in Ocular Melanoma

Study examines lymphatic and distant metastasis risk

GUEST EDITORIAL An Inflection Point for Retinal Therapy

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Melanomas: Clinical Decision Making with AI

Artificial intelligence support for opticians assessing small pigmented choroidal lesions